Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Xcovery, a US Affiliate of China's Betta, Acquires Majority Stake in Meryx

publication date: Dec 7, 2021

Xcovery, a Florida oncology biopharma, acquired a controlling stake in Meryx, a clinical stage North Carolina immuno-oncology company. Xcovery is backed largely by Betta Pharma of Hangzhou, which has formed several partnerships with western companies. Meryx develops small molecule, oral inhibitors of Mer receptor tyrosine kinases (RTK) that lower tumor growth and promote macrophage activity in hematologic and solid malignancies. Xcovery believes there are synergies between the two companies. Terms of the agreement were not disclosed. More details....

Stock Symbol: (SHZ: 300558)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.